ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2024
A comprehensive site-specific analysis of patient-specific quality assurance based on dose volume histogram of RapidArc treatment delivery.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Site-Specific Assessment of Statistical Process Control to Set Tolerance and Action Limits for Patient-Specific Quality Assurance in RapidArc Treatment Delivery.Journal of biomedical physics & engineering · 2025Article
- Impact of iso-dose levels on pre-treatment quality assurance in volumetric modulated arc therapy.Radiological physics and technology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The current study aims to evaluate the use of dose-volume histogram (DVH) metrics as part of a comprehensive pre-treatment quality assurance (PSQA) protocol for RapidArc treatment delivery. Materials and methods: A total of ninety patients were included in this study, with the patient population divided into four groups: Brain (n = 15), Head and Neck (H & N) (n = 30), Thorax (n = 15), and Pelvis (n = 30) RapidArc plans. The delivered dose was assessed using the Octavius 4D 1500 detector array and the Verisoft DVH application, focusing on DVH-related errors pertaining to targets and organ-at-risk (OARs). Additionally, three-dimensional local and global gamma passing rates were analyzed in the axial, coronal, and sagittal planes using various gamma criteria, including 3 mm/3%, 3 mm/2%, 2 mm/3%, and 2 mm/2%. Results: All treatment plans met the action level requirement, achieving a gamma acceptance rate exceeding 95% with a 3%/3 mm criterion. Among the anatomical planes, the transverse plane consistently exhibited the highest passing rates for various global gamma criteria across all treatment sites. Local gamma analysis revealed that the coronal plane had the highest passing rates for thorax and pelvis sites compared to other planes. DVH analysis indicated that doses to target volumes remained within specified tolerances for all cases. The most significant OAR dose discrepancies were observed in the H&N region. Conclusion: Integrating DVH metrics into the RapidArc PSQA protocol can yield clinically significant results closely aligned with the gamma index. It was observed that a single action-level approach cannot be universally applied to DVH metrics across different anatomical sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.